Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence?

Cancers (Basel). 2022 Nov 16;14(22):5616. doi: 10.3390/cancers14225616.

Abstract

Venous thromboembolism (VTE) disease is the second leading cause of mortality in cancer patients. In the general population, the annual incidence of a thromboembolic event is about 117 cases per 100,000 persons, but cancer increases this risk about fourfold, while in patients receiving chemotherapy and surgical treatment, it is about sevenfold. Oral squamous cell carcinoma (OSCC) is the most common form of oral cancer and represents a multistep process in which environmental factors and genetic alterations are implicated. Thrombotic risk is considered empirically low in OSCC patients, although few data are available. Having limited information available may result in poor awareness of VTE prevention in OSCC, risking jeopardising the oncologic treatment and increasing the morbidity and mortality among these patients. In this paper, the topic of OSCC-associated thrombosis will be discussed.

Keywords: cancer-associated thrombosis; oral cancer; oral squamous cell carcinoma; venous thromboembolism.

Publication types

  • Review

Grants and funding

This research received no external funding.